Search PubMed⌕ Search

Biomedical subjects

A R Cananzi

Publications and source records attributed to A R Cananzi.

22 records · Page 2Linked to original sources
PubMedDate not supplied

Platelet alpha granule secretion in cerebral ischemia: effect of short and long term low dose aspirin treatment.

The effect of short and long-term therapy with aspirin (50 mg/day) on platelet alpha granule secretion was studied in 11 healthy controls and 57 patients suffering from transient cerebral ischemic attacks (TIA) with and without accompanying diabetes and hypertension. Plasma levels of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF 4) were measured as indicators of platelet alpha granule secretion. beta-TG and PF 4 levels were increased following cerebral ischemia. Aspirin treatment failed to suppress plasma levels of both proteins when measured a month and then a year after initiation of treatment. Therefore, these proteins may be poor indicators of platelet inhibition by aspirin.

Adult↗
PubMedDate not supplied

Platelet as a model to test autonomic function in migraine.

In order to evaluate the role of the sympathetic autonomic nervous system (SANS) in common migraine we measured platelet catecholamine levels in a group of patients and in control subjects after 1 and 30 min of supine rest. Common migraine patients showed, at 1 min of supine rest, higher platelet norepinephrine (NE) content in comparison with the controls. This result may reflect a decreased release of platelet dense bodies in migraineurs. The same patients showed after 30' of supine rest a hardly significant increase of platelet NE levels in contrast to the clearly significant increase found in controls. These findings support the hypothesis of sympathetic hypofunction in migraine.

Adult↗
PubMedDate not supplied

Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction.

After 7 and 90 days of treatment, we studied the effect of picotamide, a thromboxane synthase inhibitor (450 and 900 mg/day), aspirin (150 mg/day), and aspirin plus picotamide (150 and 450 mg/day respectively) on platelet aggregation, evaluated in platelet rich plasma of 48 patients affected by ischemic stroke. Platelet aggregation, induced by collagen (1.0 and 2.0 micrograms/ml) and adenosine diphosphate (1.0 and 10 micrograms/L), was significantly increased in patients in comparison with healthy controls. Aspirin (150 mg/day) reduced collagen-induced platelet aggregation (1.0 microgram/ml) after 7 days of treatment. Picotamide (450 mg/day) reduced platelet aggregation induced by both concentrations of collagen, while the higher dose (900 mg/day) had no significant effect. Aspirin plus picotamide reduced the aggregation induced by 1.0 microgram/ml collagen and by 10 mumol/L adenosine diphosphate after 90 days of therapy. This study has shown that patients during the acute phase of stroke are characterized by an increased in vitro platelet aggregation. Aspirin may be beneficial in the acute phase of the cerebral ischemic event. Picotamide and picotamide plus aspirin could be useful for reducing platelet aggregation in long term treatment.

Acute Disease↗